Moderna, Inc. (NASDAQ:MRNA) Shares Bought by XTX Topco Ltd

XTX Topco Ltd lifted its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 889.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,256 shares of the company's stock after purchasing an additional 25,400 shares during the period. XTX Topco Ltd's holdings in Moderna were worth $1,888,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Simplicity Wealth LLC increased its position in Moderna by 31.6% during the 2nd quarter. Simplicity Wealth LLC now owns 4,838 shares of the company's stock valued at $575,000 after purchasing an additional 1,161 shares during the period. Czech National Bank lifted its holdings in Moderna by 8.9% during the second quarter. Czech National Bank now owns 63,536 shares of the company's stock worth $7,545,000 after buying an additional 5,170 shares during the period. Granite Bay Wealth Management LLC purchased a new stake in Moderna during the second quarter worth $524,000. Sequoia Financial Advisors LLC boosted its position in Moderna by 7.1% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 8,722 shares of the company's stock valued at $1,036,000 after acquiring an additional 575 shares in the last quarter. Finally, Wedmont Private Capital increased its holdings in shares of Moderna by 48.4% in the 2nd quarter. Wedmont Private Capital now owns 3,075 shares of the company's stock valued at $373,000 after acquiring an additional 1,003 shares during the period. Hedge funds and other institutional investors own 75.33% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on MRNA shares. Jefferies Financial Group cut their target price on Moderna from $65.00 to $55.00 and set a "hold" rating on the stock in a research note on Tuesday, October 15th. Hsbc Global Res upgraded shares of Moderna from a "hold" rating to a "strong-buy" rating in a research note on Monday, November 18th. Bank of America lowered their target price on shares of Moderna from $130.00 to $110.00 and set a "neutral" rating for the company in a research note on Friday, September 13th. Sanford C. Bernstein initiated coverage on Moderna in a research report on Thursday, October 17th. They set a "market perform" rating and a $55.00 price target on the stock. Finally, HSBC upgraded Moderna from a "hold" rating to a "buy" rating and set a $58.00 price objective for the company in a report on Monday, November 18th. Three analysts have rated the stock with a sell rating, twelve have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $83.33.

Insider Buying and Selling

In related news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO James M. Mock sold 715 shares of Moderna stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. This represents a 7.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 2,850 shares of company stock valued at $134,560. 15.70% of the stock is owned by company insiders.

Moderna Stock Performance

NASDAQ:MRNA traded up $1.50 during mid-day trading on Friday, hitting $44.44. The company's stock had a trading volume of 8,735,641 shares, compared to its average volume of 10,344,880. The business's fifty day moving average is $50.27 and its two-hundred day moving average is $87.33. The stock has a market cap of $17.10 billion, a price-to-earnings ratio of -7.64 and a beta of 1.58. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna, Inc. has a 1 year low of $35.80 and a 1 year high of $170.47.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company's revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.39) earnings per share. Analysts anticipate that Moderna, Inc. will post -9.32 EPS for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.